Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma.
van der Zalm AP, Dings MPG, Manoukian P, Boersma H, Janssen R, Bailey P, Koster J, Zwijnenburg D, Volckmann R, Bootsma S, Waasdorp C, van Mourik M, Blangé D, van den Ende T, Oyarce CI, Derks S, Creemers A, Ebbing EA, Hooijer GK, Meijer SL, van Berge Henegouwen MI, Medema JP, van Laarhoven HWM, Bijlsma MF. van der Zalm AP, et al. Among authors: meijer sl. Commun Med (Lond). 2024 May 17;4(1):89. doi: 10.1038/s43856-024-00512-z. Commun Med (Lond). 2024. PMID: 38760583
Transcriptional and functional profiling identifies inflammation and endothelial-to-mesenchymal transition as potential drivers for phenotypic heterogeneity within a cohort of endothelial colony forming cells.
Laan SNJ, de Boer S, Dirven RJ, van Moort I, Kuipers TB, Mei H, Bierings R, Eikenboom J; SYMPHONY consortium. Laan SNJ, et al. J Thromb Haemost. 2024 Apr 2:S1538-7836(24)00176-4. doi: 10.1016/j.jtha.2024.03.018. Online ahead of print. J Thromb Haemost. 2024. PMID: 38574861 Free article.
Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma.
Henckens SPG, Liu D, Gisbertz SS, Kalff MC, Anderegg MCJ, Crull D, Daams F, van Dalsen AD, Dekker JWT, van Det MJ, van Duijvendijk P, Eshuis WJ, Groenendijk RPR, Haveman JW, van Hillegersberg R, Luyer MDP, Olthof PB, Pierie JEN, Plat VD, Rosman C, Ruurda JP, van Sandick JW, Sosef MN, Voeten DM, Vijgen GHEJ, Bijlsma MF, Meijer SL, Hulshof MCCM, Oyarce C, Lagarde SM, van Laarhoven HWM, van Berge Henegouwen MI; IVORY study group. Henckens SPG, et al. Among authors: meijer sl. Br J Surg. 2024 Jan 31;111(2):znae034. doi: 10.1093/bjs/znae034. Br J Surg. 2024. PMID: 38387083 Free PMC article.
Vertical tumor-positive resection margins and the risk of residual neoplasia after endoscopic resection of Barrett's neoplasia: a nationwide cohort with pathology reassessment.
van Tilburg L, Verheij EPD, van de Ven SEM, van Munster SN, Weusten BLAM, Herrero LA, Nagengast WB, Schoon EJ, Alkhalaf A, Bergman JJGHM, Pouw RE, Oudijk L, Meijer SL, Jansen M, Doukas M, Koch AD; Dutch Barrett Expert Centers and the Dutch Barrett Expert Centers Study Group. van Tilburg L, et al. Among authors: meijer sl. Endoscopy. 2024 Apr 5. doi: 10.1055/a-2272-9794. Online ahead of print. Endoscopy. 2024. PMID: 38378018 Free article. Clinical Trial.
Exotic Dark Matter Search with the Majorana Demonstrator.
Arnquist IJ, Avignone FT, Barabash AS, Barton CJ, Bhimani KH, Blalock E, Bos B, Busch M, Buuck M, Caldwell TS, Chan YD, Christofferson CD, Chu PH, Clark ML, Cuesta C, Detwiler JA, Efremenko Y, Ejiri H, Elliott SR, Giovanetti GK, Green MP, Gruszko J, Guinn IS, Guiseppe VE, Haufe CR, Henning R, Hervas Aguilar D, Hoppe EW, Hostiuc A, Kidd MF, Kim I, Kouzes RT, Lannen V TE, Li A, Lopez AM, López-Castaño JM, Martin EL, Martin RD, Massarczyk R, Meijer SJ, Mertens S, Oli TK, Othman G, Paudel LS, Pettus W, Poon AWP, Radford DC, Rager J, Reine AL, Rielage K, Ruof NW, Schaper DC, Tedeschi D, Varner RL, Vasilyev S, Wilkerson JF, Wiseman C, Xu W, Yu CH, Zhu BX; <span class="sc">Majorana</span> Collaboration. Arnquist IJ, et al. Among authors: meijer sj. Phys Rev Lett. 2024 Jan 26;132(4):041001. doi: 10.1103/PhysRevLett.132.041001. Phys Rev Lett. 2024. PMID: 38335333
Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.
Meijer SE, Halutz O, Adler A, Levytskyi K, Tau L, Dekel M, Cohen-Poradosu R, Katchman E, Shasha D, Ablin J, Choshen G, Jacob G, Wasserman A, Ingbir M, Cohen YC, Perry C, Ram R, Herishanu Y, Bar On Y, van Thijn E, Rutsinsky N, Harari S, Stern A, Ben-Ami R, Paran Y. Meijer SE, et al. J Infect Chemother. 2024 Mar;30(3):271-275. doi: 10.1016/j.jiac.2023.10.022. Epub 2023 Nov 7. J Infect Chemother. 2024. PMID: 37944697
677 results